The ALS Never Surrender Foundation has received a $300,000 grant from the ALS Association to support the iNVOLVE/eNGAGE app for the condition.

The mobile technology app will be used in Motor Neuron Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) patient progression research trials in the US.

The ALS iNVOLVE/eNGAGE app will partner with experts from Google AI, IBM Watson, and Apple for physical measurement data analysis.

It also includes a partnership with Aural Analytics for speech and breathing analysis.

The app is designed to allow patients to track over 80 metrics of key information such as motion, muscle control, dexterity, breathing, speech and others on a remote global platform.

It will operate on Claris FileMaker’s Workplace Innovation Platform and help develop a patient progression database for researchers to study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Expected to start this month across five ALS medical facilities, the trials will include 50 patients of all ages, genders and geographies.

ALS eNGAGE CEO Nic Friedman said: “Current progression surveys are subjective, and occasionally patients do not accurately report the changes with their mobility, mostly out of the desire to remain positive, or to shield their family members from their suffering and disease progression.

“With this funding, we will see the role this technology can play in patient self-monitoring. Additionally, our mobile app enables clinical support teams to proactively respond to their patients’ needs as their symptoms change.

“It will also provide critical data to researchers who are trying to identify trends to assess the impact of new therapies for MND/ALS treatments.”

ALS is a rare progressive neurodegenerative disease caused by the dysfunction of nerves that control voluntary muscular movement.

The disorder is also known as Lou Gehrig’s disease.

Friedman added: “Through our ALS iNVOLVE/eNGAGE app, researchers can now gather 116,000 data points per patient from diagnosis until death as opposed to other technologies, which gather just 240 points of data per patient for the same time period.”